Aladar Szalay Sells 6,403 Shares of Genelux Co. (NASDAQ:GNLX) Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 6,403 shares of the stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $3.25, for a total value of $20,809.75. Following the transaction, the insider now owns 1,249,327 shares in the company, valued at approximately $4,060,312.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Wednesday, May 1st, Aladar Szalay sold 33,061 shares of Genelux stock. The shares were sold at an average price of $3.30, for a total value of $109,101.30.
• On Wednesday, April 24th, Aladar Szalay sold 8,064 shares of Genelux stock. The shares were sold at an average price of $3.50, for a total value of $28,224.00.
• On Monday, April 22nd, Aladar Szalay sold 14,331 shares of Genelux stock. The shares were sold at an average price of $3.53, for a total value of $50,588.43.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The shares were sold at an average price of $3.53, for a total value of $171,850.99.

Genelux Stock Performance

Shares of Genelux stock opened at $3.48 on Friday. The company’s fifty day simple moving average is $5.41 and its 200-day simple moving average is $10.31. Genelux Co. has a 1 year low of $3.06 and a 1 year high of $40.98.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings data on Friday, March 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.04). Equities analysts forecast that Genelux Co. will post -0.81 earnings per share for the current year.

Institutional Investors Weigh In On Genelux

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Genelux by 1,660.1% during the third quarter. Vanguard Group Inc. now owns 980,993 shares of the company’s stock worth $24,025,000 after buying an additional 925,258 shares in the last quarter. D.A. Davidson & CO. acquired a new stake in Genelux during the third quarter worth $237,000. Advisor Resource Council acquired a new stake in Genelux during the fourth quarter worth $233,000. Barclays PLC boosted its stake in Genelux by 516.4% during the third quarter. Barclays PLC now owns 3,384 shares of the company’s stock worth $83,000 after buying an additional 2,835 shares in the last quarter. Finally, Whittier Trust Co. acquired a new stake in Genelux during the third quarter worth $175,000. Institutional investors and hedge funds own 37.33% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the company. HC Wainwright lowered their price target on Genelux from $35.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd. Benchmark restated a “speculative buy” rating and issued a $30.00 price objective on shares of Genelux in a research note on Wednesday, April 3rd.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.